<p>Tanshinone IIA Reverses Gefitinib-Resistance In Human Non-Small-Cell Lung Cancer Via Regulation Of VEGFR/Akt Pathway</p>

201934 citationsJournal Articlegold Open Access

Authors

Zhilin Luo · Chongqing Medical University

Hong Zhang · Chongqing Medical University

Tianhu Wang · Chongqing Medical University

Abstract

We found that Tan IIA could enhance gefitinib sensitivity in gefitinib-resistance NSCLC cells. Therefore, combination of gefitinib with Tan IIA might be considered as a therapeutic approach for the treatment of gefitinib-resistant NSCLC.

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Cancer, Hypoxia, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: OncoTargets and Therapy

Volume Volume 12, pp. 9355-9365

DOI: 10.2147/ott.s221228

Field-Weighted Citation Impact: 3.98

Command Palette